Publicacións en colaboración con investigadores/as de Universidade de Santiago de Compostela (23)

2018

  1. The psychosocial impact of inflammatory bowel disease and its management. From the patients’ perspective

    Gastroenterologia y Hepatologia, Vol. 41, Núm. 10, pp. 640-642

2015

  1. High sodium intake is associated with self-reported rheumatoid arthritis: A cross sectional and case control analysis within the SUN cohort

    Medicine (United States), Vol. 94, Núm. 37

  2. Predictors of treatment failure and mortality in native septic arthritis

    Clinical Rheumatology, Vol. 34, Núm. 11, pp. 1961-1967

2014

  1. BIOBADASER, BIOBADAMERICA, and BIOBADADERM: Safety registers sharing commonalities across diseases and countries

    Clinical and Experimental Rheumatology, Vol. 32, pp. S163-S167

  2. Documento práctico para el uso de abatacept subcutáneo

    Reumatologia Clinica, Vol. 10, Núm. 4, pp. 218-226

  3. Observational study of optimization of biologic therapies in rheumatoid arthritis: A single-centre experience

    Rheumatology International, Vol. 34, Núm. 8, pp. 1059-1063

  4. Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies

    Joint Bone Spine, Vol. 81, Núm. 1, pp. 41-50

  5. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: A systematic review and meta-analysis of randomized controlled trials and long-term extension studies

    Rheumatology (United Kingdom), Vol. 53, Núm. 10, pp. 1872-1885

  6. Safety profile of protein kinase inhibitors in rheumatoid arthritis: Systematic review and meta-analysis

    Annals of the Rheumatic Diseases, Vol. 73, Núm. 5, pp. 871-882

2013

  1. El uso de abatacept en artritis reumatoide: Revisión de la evidencia y recomendaciones

    Reumatologia Clinica, Vol. 9, Núm. 1, pp. 5-17

  2. Le facteur rhumatoïde ne semble pas prédire la réponse aux anti-TNF α dans la polyarthrite rhumatoïde: expérience de trois centres

    Revue du Rhumatisme (Edition Francaise)

  3. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis

    Seminars in Arthritis and Rheumatism, Vol. 43, Núm. 1, pp. 9-17

  4. Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: Three centers experience

    Joint Bone Spine

2012

  1. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: Data from the Spanish registry BIOBADASER 2.0

    Annals of the Rheumatic Diseases, Vol. 71, Núm. 3, pp. 382-385

  2. Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review

    Seminars in Arthritis and Rheumatism, Vol. 42, Núm. 1, pp. 89-103

  3. Infections in patients with rheumatic diseases treated with TNF antagonists

    Current Pharmaceutical Biotechnology, Vol. 13, Núm. 8, pp. 1418-1425

2011

  1. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0

    Rheumatology, Vol. 50, Núm. 1, pp. 85-92

2010

  1. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

    Annals of the Rheumatic Diseases, Vol. 69, Núm. 10, pp. 1751-1755

2007

  1. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists

    Annals of the Rheumatic Diseases, Vol. 66, Núm. 7, pp. 880-885

  2. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

    Arthritis Care and Research, Vol. 57, Núm. 5, pp. 756-761